BP1, a homeoprotein, is significantly expressed in prostate adenocarcinoma and is concordant with prostatic intraepithelial neoplasia

Modern Pathology

Volumn 22, Issue 1, 2009, Pages 1-6

  Schwartz, Arnold M ^a   Man, Yan Gao ^b   Rezaei, M Katayoon ^a   Simmens, Samuel J ^a   Berg, Patricia E ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

BP1; PIN; Prostate carcinoma; Tissue microarray

Indexed keywords

HOMEODOMAIN PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN BP1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION;

EID: 58149175829     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.168     Document Type: Article

References (22)

1. Drago JR. The role of new modalities in the early detection and diagnosis of prostate cancer. CA Cancer J Clin 1989;39:326-336.
2. Epstein JI, Srigley J, Grignon D. Recommendations for the reporting of prostate carcinoma. Hum Pathol 2007;38:1305-1309.
3. Chase MB, Fu S, Haga SB, et al. BP1, a homeodomain-containing isoform of DLX4, represses the beta-globin gene. Mol Cell Biol 2002;22:2505-2514.
4. Fu SW, Schwartz A, Stevenson H, et al. Correlation of expression of BP1, a homeobox gene, with estrogen receptor status in breast cancer. Breast Cancer Res 2003;5:82-87.
5. Man YG, Fu SW, Schwartz AE, et al. Expression of BP1, a homeobox gene, correlates with progression and invasion of mammary ductal carcinoma. Breast Cancer Res Treat 2005;90:241-247.
6. Schmitt FC. Multistep progression from an oestrogen-dependent growth towards an autonomous growth in breast carcinogenesis. Eur J Cancer 1995;31A:2049-2052.
7. Man YG, Martinez A, Avis IM, et al. Phenotypically different respiratory epithelial cells with hnRNPA2/B1 over-expression display similar genetic alterations. Am J Respir Cell Mol Biol 2000;23:636-645.
8. Sheikh MS, Garcia M, Pujol P, et al. Why are estrogen receptor negative breast cancers more aggressive than the estrogen receptor positive breast cancers? Invasion Metastasis 1995;14:329-336.
9. Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 2001;10:139-151.
10. Bostwick DG, Qian J. High grade prostatic intraepithelial neoplasia. Mod Pathol 2004;17:360-379.
11. Ashida S, Nakagawa H, Katagiri T, et al. Molecular features of the transition from PIN to prostate cancer: genome-wide gene expression profiles of prostate cancers and PIN. Cancer Res 2004;64:5963-5972.
12. Konishi N, Shimada K, Ishida E. Molecular pathology of prostate cancer. Pathol Int 2005;55:531-539.
13. Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39:41-51.
14. Gonzalgo ML, Isaacs WB. Molecular pathways to prostate cancer. J Urol 2003;170:2444-2452.
15. Haga SB, Fu S, Karp JE, et al. BP1, a new homeobox gene, is frequently expressed in acute leukemias. Leukemia 2000;14:1867-1875.
16. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantitation of protein expression in tissue microarrays. Nat Med 2002;8:1323-1327.
17. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-1949.
18. Rubin MA, Dunn R, Strawderman M, et al. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 2002;26:312-319.
19. Zhang D, Salto-Tellez M, Putti TC, et al. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast caner. Mod Pathol 2003;16:79-84.
20. Packeisen J, Korsching E, Herbst H, et al. Demystified tissue microarray technology. Mod Pathol 2003;56:198-204.
21. Liu X, Minin V, Huang Y. Statistical methods for analyzing tissue microarray data. J Biopharm Stat 2004;14:671-685.
22. Stevenson HS, Fu S, Pinzone JJ, et al. BP1 transcriptionally activates bcl-2 and inhibits TNFα-induced cell death in MCF7 breast cancer cells. Breast Cancer Res 2007;9:R60.